Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02110706 · ClinicalTrials.gov registry record · Phase 2
BeatMG: Phase II Trial of Rituximab In Myasthenia Gravis
A Phase 2 study of Myasthenia Gravis, sponsored by Yale University.
- Completed
- Registry status
- Phase 2
- Development phase
- 52
- Enrollment target
- 20
- Study locations
NCT02110706: Completed Phase 2 study of Myasthenia Gravis, sponsored by Yale University.
NCT02110706 is a Phase 2 study of Myasthenia Gravis that has completed, run by Yale University. The registered enrollment target is 52 participants, below the 190-participant average among 32 other Myasthenia Gravis trials with a reported enrollment target (73% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02110706, a Phase 2 study of Myasthenia Gravis, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 52 participants
- Enrollment target
- 20
- Study locations
Study Summary
The specific primary objective of this study is to determine whether rituximab is a safe and beneficial therapeutic for Myasthenia Gravis (MG) that warrants further study in a phase III efficacy trial.
Primary Outcome
Percent of subjects that achieve a ≥ 75% reduction in mean daily prednisone dose in the 4 weeks prior to week 52 and have clinical improvement or no significant worsening of symptoms (≤ 2 point increase in MGC score) as compared to 4-week period prior to randomization and initiation of treatment.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Rituximab
Study Locations (20)
New York
- SUNY Downstate Medical Center - Brooklyn
- SUNY Buffalo - Buffalo
- Columbia University Medical Center - New York
- Weill Cornell Medical Center - New York
- University of Rochester - Rochester
- SUNY Stony Brook - Stony Brook
- Montefiore Medical Center - The Bronx
California
- University of California - Davis - Davis
- University of California - Los Angeles - Los Angeles
Ohio
- University of Cincinnati - Cincinnati
- Ohio State University - Columbus
Alabama
- University of Alabama at Birmingham - Birmingham
Colorado
- University of Colorado - Denver - Denver
Connecticut
- Yale School of Medicine, Department of Neurology - New Haven
Florida
- University of Miami School of Medicine - Miami
Georgia
- Emory University - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2014-05 |
| Est. Completion | 2018-05 |
| Phase | Phase 2 |
What the finished NCT02110706 record still lists
NCT02110706 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 52 participants, a relatively small participant target, below the 190-participant average among 32 other Myasthenia Gravis trials with a reported enrollment target (73% lower).
The record links to 1 condition, with Myasthenia Gravis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02110706 names 20 study sites across 12 states, led by New York, California, Ohio.
Frequently Asked Questions
What is clinical trial NCT02110706 about?
NCT02110706 is a clinical study titled "BeatMG: Phase II Trial of Rituximab In Myasthenia Gravis". The specific primary objective of this study is to determine whether rituximab is a safe and beneficial therapeutic for Myasthenia Gravis (MG) that warrants further study in a phase III efficacy trial.
What is the current status of trial NCT02110706?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 52 participants. The study started on 2014-05. Estimated completion is 2018-05.
What conditions does trial NCT02110706 study?
This clinical trial studies the following conditions: Myasthenia Gravis.
What interventions are being tested in trial NCT02110706?
The interventions under investigation include: Placebo (DRUG), Rituximab (DRUG).
Who is sponsoring clinical trial NCT02110706?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02110706 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myasthenia Gravis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02110706's enrollment target sits among peer trials
52 23rd of 32 higher than 10 of 32 other Myasthenia Gravis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Myasthenia Gravis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis
RECRUITING · Phase 2
-
ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod
RECRUITING · Phase 2
-
Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis
RECRUITING · Phase 2
-
A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis
RECRUITING · Phase 2
-
A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness
COMPLETED · Phase 2
-
A Study of RVT-1401 in Myasthenia Gravis (MG) Patients
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02630121 · 52 participants · Phase 4
Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea
- NCT03629171 · 52 participants · Phase 2
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
- NCT04128748 · 52 participants · Phase 1
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
- NCT04150497 · 52 participants · Phase 1
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia